First Trust Advisors LP trimmed its position in Pfizer Inc. (NYSE:PFE) by 6.2% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 4,114,097 shares of the biopharmaceutical company’s stock after selling 271,311 shares during the period. First Trust Advisors LP owned about 0.07% of Pfizer worth $149,259,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. HC Financial Advisors Inc. bought a new position in Pfizer during the fourth quarter valued at $2,685,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp lifted its position in Pfizer by 15.0% during the fourth quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 3,082,158 shares of the biopharmaceutical company’s stock valued at $111,636,000 after purchasing an additional 402,638 shares during the last quarter. Dixon Hubard Feinour & Brown Inc. VA lifted its position in Pfizer by 1.5% during the fourth quarter. Dixon Hubard Feinour & Brown Inc. VA now owns 130,566 shares of the biopharmaceutical company’s stock valued at $4,729,000 after purchasing an additional 1,925 shares during the last quarter. CNB Bank bought a new position in Pfizer during the fourth quarter valued at $2,057,000. Finally, Envestnet Asset Management Inc. lifted its position in Pfizer by 10.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 1,086,886 shares of the biopharmaceutical company’s stock valued at $39,367,000 after purchasing an additional 102,521 shares during the last quarter. Hedge funds and other institutional investors own 68.95% of the company’s stock.
Several equities analysts have commented on PFE shares. BMO Capital Markets increased their price objective on shares of Pfizer from $42.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, August 1st. Jefferies Financial Group set a $39.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Tuesday, July 31st. JPMorgan Chase & Co. reiterated a “buy” rating and set a $42.00 price objective on shares of Pfizer in a research report on Wednesday, July 11th. Barclays set a $40.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research report on Wednesday, August 29th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a research report on Tuesday, July 3rd. Two investment analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and an average price target of $42.40.
In other news, insider Laurie J. Olson sold 10,214 shares of the stock in a transaction on Monday, August 13th. The shares were sold at an average price of $41.00, for a total value of $418,774.00. Following the sale, the insider now owns 72,672 shares of the company’s stock, valued at $2,979,552. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Ian C. Read sold 486,753 shares of the firm’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $37.36, for a total transaction of $18,185,092.08. Following the completion of the transaction, the chief executive officer now directly owns 1,145,693 shares in the company, valued at approximately $42,803,090.48. The disclosure for this sale can be found here. In the last three months, insiders sold 761,230 shares of company stock worth $29,054,690. Insiders own 0.06% of the company’s stock.
Shares of PFE opened at $43.78 on Friday. Pfizer Inc. has a twelve month low of $33.20 and a twelve month high of $45.81. The firm has a market capitalization of $262.34 billion, a PE ratio of 16.52, a PEG ratio of 2.23 and a beta of 0.96. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.41.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.07. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The business had revenue of $13.47 billion for the quarter, compared to the consensus estimate of $13.30 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. The business’s revenue for the quarter was up 4.4% on a year-over-year basis. On average, equities research analysts predict that Pfizer Inc. will post 2.99 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.11%. The ex-dividend date is Thursday, November 8th. Pfizer’s dividend payout ratio is currently 51.32%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
See Also: Market Capitalization
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.